- Home
- ALEC vs CRBP Comparison
ALEC vs CRBP Comparison
Compare ALEC & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALEC | CRBP |
|---|---|---|
| Founded | 2013 | 2009 |
| Country | United States | United States |
| Employees | 103 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 158.8M | 184.4M |
| IPO Year | 2019 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ALEC | CRBP |
|---|---|---|
| Price | $1.54 | $8.98 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | $4.83 | ★ $45.50 |
| AVG Volume (30 Days) | ★ 879.4K | 447.6K |
| Earning Date | 05-04-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $21,045,000.00 | $4,822,272.00 |
| Revenue This Year | $2.03 | N/A |
| Revenue Next Year | $29.87 | $116.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 97.62 |
| 52 Week Low | $1.09 | $7.12 |
| 52 Week High | $3.40 | $20.56 |
Technical Indicators
Market Signals| Indicator | ALEC | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 40.32 | 50.69 |
| Support Level | $1.37 | $7.86 |
| Resistance Level | $1.60 | $9.73 |
| Average True Range (ATR) | 0.14 | 0.45 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 18.71 | 35.51 |
Price Performance
Historical ComparisonAbout ALEC Alector Inc.
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.